R&D Day 2021
December 02, 2021 – Virtual
Download the agenda (PDF 0.2 MB)
Download the presentation (PDF 32 MB)
Download the podcast (MP3 60 MB)
Read the media release
Watch the webcast:
Main Audience Event Link
Audience Event Link China
We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Investors Event Calendar
Environmental, Social and Governance (ESG)
ESG Updates: Oct 27, 2021 (PDF 0.5 MB) | July 22, 2021 (PDF 1.8 MB) | Apr 28, 2021 (PDF 0.3 MB) | Jan 27, 2021 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessments Webinars
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Novartis ESG Investor Day 2021
Novartis shared progress on its most material ESG topics.
Stocks
Media Releases
Pulse Updates
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Novartis COVID-19 Information Center
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay Up-to-Date
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland